Your browser doesn't support javascript.
loading
Oral Adverse Events Associated with BRAF and MEK Inhibitors in Melanoma Treatment: A Narrative Literature Review.
Basilicata, Michele; Terrano, Vincenzo; D'Aurelio, Alessandro; Bruno, Giovanni; Troiani, Teresa; Bollero, Patrizio; Napolitano, Stefania.
Affiliation
  • Basilicata M; UOSD Special Care Dentistry, Department of Experimental Medicine and Surgery, University of Roma Tor Vergata, 00133 Rome, Italy.
  • Terrano V; UniCamillus-Saint Camillus, International University of Health Sciences, 00131 Rome, Italy.
  • D'Aurelio A; Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80138 Napoli, Italy.
  • Bruno G; UOSD Special Care Dentistry, Department of Experimental Medicine and Surgery, University of Roma Tor Vergata, 00133 Rome, Italy.
  • Troiani T; Department of Neuroscience, University of Padua, 35121 Padova, Italy.
  • Bollero P; Department of Industrial Engineering, University of Tor Vergata, 00133 Rome, Italy.
  • Napolitano S; Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80138 Napoli, Italy.
Healthcare (Basel) ; 12(1)2024 Jan 02.
Article in En | MEDLINE | ID: mdl-38201012
ABSTRACT

BACKGROUND:

Melanoma cancer represents the most lethal type of skin cancer originating from the malignant transformation of melanocyte cells. Almost 50% of melanomas show the activation of BRAF mutations. The identification and characterization of BRAF mutations led to the development of specific drugs that radically changed the therapeutic approach to melanoma.

METHODS:

We conducted a narrative review of the literature according to a written protocol before conducting the study. This article is based on previously conducted studies. We identified articles by searching electronic databases (Medline, Google Scholar and PubMed). We used a combination of "melanoma", "Braf-Mek inhibitors", " targeted therapy" and "oral side effects".

RESULTS:

Eighteen studies were reported in this article showing the relationship between the use of targeted therapy in melanoma cancer and the development of oral side effects, such as mucositis, hyperkeratosis and cellular proliferation.

CONCLUSION:

Targeted therapy plays an important role in the treatment of melanoma cancer, showing a notable increase in response rate, prolonged progression-free survival and overall survival in BRAF-mutated melanoma patients. Oral side effects represent a common finding over the course of treatment. However, these adverse effects can be easily managed in a multidisciplinary approach involving collaboration between medical oncologists and dental doctors.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline / Prognostic_studies / Risk_factors_studies Language: En Journal: Healthcare (Basel) Year: 2024 Type: Article Affiliation country: Italy

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline / Prognostic_studies / Risk_factors_studies Language: En Journal: Healthcare (Basel) Year: 2024 Type: Article Affiliation country: Italy